US 7,537,765 B2
	Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
Karl Salzwedel, Olney, Md. (US); Feng Li, Gaithersburg, Md. (US); Carl T. Wild, Gaithersburg, Md. (US); Graham P. Allaway, Darnestown, Md. (US); and Eric O. Freed, Frederick, Md. (US)
Assigned to Panacos Pharmaceuticals, Inc., Gaithersburg, Md. (US); and The United States of America as represented by the Department of Health and Human Services, Washington, D.C. (US)
Filed on May 24, 2004, as Appl. No. 10/851,637.
Application 10/851637 is a continuation in part of application No. 10/766528, filed on Jan. 29, 2004.
Claims priority of provisional application 60/496660, filed on Aug. 21, 2003.
Claims priority of provisional application 60/443180, filed on Jan. 29, 2003.
Prior Publication US 2005/0015039 A1, Jan. 20, 2005
Int. Cl. A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 38/00 (2006.01)

U.S. Cl. 424—184.1  [530/300; 424/186.1; 424/187.1; 424/188.1]

40 Claims

1. An isolated polypeptide comprising 10 amino acids downstream from the CA-SP1 cleavage site of HIV-1 Gag, wherein said polypeptide contains a substitution of Ala to Val at a position corresponding to residue 364 of HIV-1 Gag (residue 1 of SP1) as compared to the sequence of either the wild type strain NL4-3 or the wild type strain RF.